5-Amino-1MQ keeps coming up as the fat loss compound that isn't a GLP-1, and the reason is its mechanism. It doesn't suppress appetite. It removes a metabolic brake that fat cells put on themselves. That is a genuinely different lever from the GLP class, which makes it interesting, but the honest picture is that all the compelling data is preclinical and there are no human trials yet. Here is what it actually does and where the evidence stops.

For research and educational purposes only. Not medical advice.

What it is

5-Amino-1MQ (5-amino-1-methylquinolinium) is a synthetic small molecule, not a peptide, with the formula C10H12N2O. It selectively inhibits NNMT (nicotinamide N-methyltransferase), an enzyme overexpressed in white adipose tissue in obesity. It is usually taken orally, which sets it apart from most compounds in the injectable research space.

The mechanism, in plain terms

NNMT sits at a metabolic crossroads. It consumes nicotinamide, a precursor to NAD+, and SAM, the cell's main methyl donor. In obese fat tissue NNMT is overexpressed, which drains nicotinamide away from NAD+ production and pushes adipocytes toward storage.

5-Amino-1MQ blocks NNMT. With the enzyme inhibited, nicotinamide is preserved and re-enters the NAD+ salvage pathway specifically in fat cells. Higher NAD+ supports the sirtuins (SIRT1, SIRT3) that drive energy expenditure and fat oxidation. The net effect in models is a fat cell that burns more and stores less.

The point most worth understanding: this works upstream of the appetite pathway entirely. Where GLP-1 compounds reduce how much you eat, 5-Amino-1MQ changes how fat cells behave. It is a peripheral metabolic lever, not a central appetite one.

What the research shows

The preclinical case is real and consistent:

In the anchor study (Neelakantan et al., 2018), diet-induced obese mice given 5-Amino-1MQ showed reduced body weight and fat mass, driven by increased adipocyte energy expenditure rather than reduced food intake. The same line of work also reported roughly 30% reductions in plasma total cholesterol in treated animals.

Earlier target validation (Kraus et al., 2014, Nature) established that knocking down NNMT in fat tissue protected mice against diet-induced obesity and improved insulin sensitivity, which is what made NNMT a druggable metabolic target in the first place.

In cell culture, 5-Amino-1MQ raised intracellular NAD+, lowered its byproduct marker (1-MNA, confirming the enzyme was actually being blocked), and suppressed lipogenesis in adipocytes.

The gap that matters

Every finding above is preclinical. There is no human Phase 1 dose-finding study, no published human pharmacokinetic data, and no placebo-controlled human trial in any indication for 5-Amino-1MQ. Human reports of fat loss are anecdotal and unquantified.

The "no appetite suppression" claim illustrates the caution needed. It is true in the sense that the 11-day mouse study saw fat loss without reduced eating. That is not the same as "preserves appetite over a year of human use." The mechanism is promising and the target is validated, but nobody should expect GLP-1 scale results from a compound with zero human trial data.

One nuance worth knowing: because 5-Amino-1MQ works by preserving nicotinamide rather than adding it, it is a different lever than NMN or NR precursor loading. It plugs the drain instead of adding more substrate. Whether the two combine additively in humans is unproven.

Dosing as reported (research context)

From the master protocol reference. This is a short-cycle, single-morning-dose compound.

Parameter	Reported approach
Oral range	50 to 150 mg/day (chloride salt)
SC alternative	500 mcg to 3.3 mg/day (less common, less documented)
Schedule	Single morning dose
Cycle	4 to 6 weeks on, 8 to 12 weeks off
Bloodwork	Glucose, insulin, liver

Reported oral ramp:

Phase	Dose
Weeks 1 to 2 (tolerance)	50 mg, single morning dose
Weeks 3 to 6 (active)	100 to 150 mg, single morning dose
Off-cycle (8 to 12 weeks)	Pause

The oral chloride salt is the preferred and better-documented route. Injectable SC protocols exist but are less common and less supported. Reported effects note energy and endurance shifts within 1 to 2 weeks, with body composition changes around weeks 4 to 6.

Where it sits

5-Amino-1MQ is one of the more mechanistically interesting metabolic compounds in the research space, and NNMT is a genuinely validated target. It is also entirely preclinical in its evidence, oral, short-cycled, and not a peptide. The right frame is a compelling mechanism with a real evidence gap: promising on paper, unproven in humans. It is best understood as a peripheral fat-cell lever that could complement rather than replace other approaches, not a standalone answer.

The open question

For anyone running metabolic research: does the peripheral NNMT approach hold up as a real fat-loss lever, or does the total absence of human data make it too early to weigh against compounds that at least have trials. And for those pairing it with NAD+ precursors, is plugging the drain plus adding substrate actually additive, or redundant. Curious where people land given the mechanism is strong but the human proof is simply not there yet.

For the full reconstitution, dosing, and bloodwork reference on every compound, the complete cheat sheet is here: The Only Peptide Cheat Sheet You'll Need

Hi all! Currently just started Reta on 1mg and for a small cut before my holiday. I have also a had a niggling AC joint pain in my shoulder for 2 years now and also currently nursing a fractured rib.

Just wanted to ask your opinions on whether I can stack Reta with bpc 157 and tb 500 to aid with recovery. Am I able to stack all 3 or maybe only the 2? I have also heard bpc 157 is best when injected directly near the injury but not necessarily the same will apply for tb 500. What kind of dosing and frequency is to be recommended too with the ‘wolverine stack’ and timelines?

Thank you all in advance!

Anbody have experimented with Adamax? Looking for feedback/dosages

Most people buying research peptides have learned to ask for a COA. Far fewer know how to read one, and the gap is where money gets wasted on underdosed or mislabelled vials.

A COA (certificate of analysis) is a lab report on a specific batch. Here is what actually matters on it, and what to ignore.

The three numbers that matter

1. Identity. Mass spec (usually MS or LC-MS) confirms that the molecule matches the label by molecular weight. If there is no identity test, then having a purity number for an unknown compound is useless.

2. Purity. HPLC gives a percentage. 98%+ is the working floor for most peptides. The number alone is not enough, though: check it's HPLC purity of the named peptide, not "total solids", which is a different and much easier number to inflate.

3. Net peptide content. This is the one almost nobody checks. A vial can be 99% pure and still contain far less actual peptide than the label mg, because lyophilised powder includes salts and water. Net peptide content (sometimes "peptide content by nitrogen") tells you how much is actually the active compound. Two vials both labelled 10mg can differ by 30% in what you are really getting.

The three ways COAs get faked

- Reused document. The same COA stapled to every batch for a year. A real COA has a batch or lot number that should match the vial. If they will not show a lot number, assume it is decorative.

- In-house testing dressed up as third party. "Tested" is meaningless if the vendor ran the test. You want a named independent lab on the document. If the lab is unnamed or is the vendor's own, treat the numbers as marketing.

- The purity bait and switch. A clean HPLC purity number with no identity test, no lot number, and no net peptide content. One real number surrounded by absences.

The 20 second check before you buy

Lot number present and matches. Independent lab named. Identity test present. HPLC purity of the named peptide at 98%+. Net peptide content stated. Miss two of those and it is not a vetted product, it is a vial with a nice PDF.

Happy to go deeper on any of these in the comments.

I built a simple self-contained web page for peptide dose calculations, mainly for people who want an easier way to calculate reconstitution, dose volume, insulin syringe units, and weekly GLP-1 / multi-agonist schedules.

It includes:

• Peptide vial + BAC water dose calculator
• U-100 insulin syringe unit conversion
• Quick dose reference table
• Slider-style inputs so it is easier to adjust values
• No tracking, no login, no account, no data upload

The main reason I made this is because I got tired of manually calculating units, vial concentration over and over again.

Of course, this is not medical advice and everyone should verify their own numbers carefully. It is just a calculator/tool to make the math easier and reduce mistakes.

Would love to hear feedback from the community, especially if there are extra features you think would make it more useful.

Link: https://bac-now.tiiny.site/en/

Epitalon sits at the center of longevity-peptide discussion, and it makes one of the boldest claims in the space: that a four-amino-acid peptide can switch telomerase back on, lengthen telomeres, and restore the pineal melatonin rhythm that fades with age. What makes it worth taking seriously is that the claim is tethered to real research, including, as of 2025, an independent study outside the lab that originated it. What keeps it honest is that the strongest evidence is still in cells, not people. This covers the mechanism, what the studies showed, and where the real gap is.

For research and educational purposes only. Not medical advice.

What it is

Epitalon is a synthetic tetrapeptide, sequence Ala-Glu-Asp-Gly (AEDG). It was derived from epithalamin, a natural pineal-gland extract, and developed in the 1980s by the Russian gerontologist Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. The body produces tiny amounts of the parent compound; the synthetic version is the simplified, reproducible analog.

The reason it holds a serious position in longevity circles despite no Western regulatory approval is the depth of research behind it. Khavinson's program ran roughly four decades and produced over 100 papers spanning animal lifespan, human aging biomarkers, telomere biology, and pineal function. That's an unusual research legacy for a compound in this category.

The two mechanisms

Epitalon is described as targeting two aging processes at once.

Telomerase activation. The headline. Telomeres are the protective caps on chromosome ends that shorten with each cell division; when they get critically short, the cell stops dividing and enters senescence. Telomerase rebuilds them, but it's switched off in most adult somatic cells. Epitalon's central claim is that it reactivates telomerase (specifically hTERT, the catalytic subunit), allowing telomere length to be maintained or extended.

Pineal and circadian restoration. The less-discussed half. Because Epitalon descends from a pineal extract, it's also studied for restoring melatonin secretion and circadian rhythm in aging individuals, where the pineal's output declines. This is why it's dosed in the evening and why sleep and circadian health come up alongside the telomere story.

What the research actually showed

Here's where precision matters, because the findings are real and the way they get described is often loose.

The foundational cell work (2003). The Khavinson group reported that in telomerase-negative human fetal fibroblasts, Epitalon induced telomerase activity and produced telomere elongation. That's the result everything traces back to: a peptide reactivating telomerase in human cells where it had been silenced.

Independent replication (2025). This is the genuinely new part, and it changes the picture. A team at Brunel University London, entirely separate from Khavinson's group, treated breast cancer cell lines and normal epithelial and fibroblast cells with Epitalon and reported dose-dependent telomere length extension, driven by hTERT and telomerase upregulation in the normal cells and by an alternative pathway (ALT) in the cancer lines. The core cell-culture mechanism is no longer a single-lab finding. (Worth noting for completeness: the paper issued a figure correction in November 2025, though the central result stands.)

Animal longevity. The rodent data is consistent across Khavinson's program: lifespan extension and reduced spontaneous tumor incidence in aged animals.

The gap that actually matters

So the skeptical framing people often apply, "it's one lab, nobody's reproduced it," is now outdated for the cell mechanism. But the real limitation is more specific and still very much open.

All of the strong telomere evidence, including the 2025 replication, is in vitro, cells in a dish. There is still no rigorous human clinical trial showing dose-dependent telomere extension, hTERT changes, or a longevity outcome in actual people. The leap from "extends telomeres in cultured human cells" to "slows aging in humans" has not been made with controlled human data. That's the honest gap: the cell biology is real and now independently supported, the human clinical proof isn't there yet.

It's also worth keeping the telomere-equals-longevity assumption itself in view. Telomere length is a biomarker of aging, but lengthening telomeres pharmacologically is not the same as proven life extension in humans, and the relationship between the two is more complicated than the simple version suggests.

So the cleanest read: Epitalon has a meaningful preclinical evidence base for telomere effects, stronger than most longevity peptides, including original work and an independent 2025 cell study. There is still no strong human clinical proof that it extends telomeres or slows aging in people.

Dosing as commonly described (community/research convention)

This schedule is the convention used in research-and-community settings, not a protocol established by the published studies. Epitalon is run in short pulsed courses rather than continuously.

Parameter	Reported convention
Course	10 to 20 day course
Frequency	Every 4 to 6 months, or annually for maintenance
Total cycle dose	~100 mg per course
Timing	Evening dosed (pineal/melatonin rationale)

The short-burst, few-times-yearly cadence reflects the theory that the telomerase and pineal effects are set in motion by a pulse rather than needing constant exposure. It's a convention, not an evidence-based standard.

Side effects

No major safety signal has emerged in the published literature. That phrasing is deliberate: the human evidence base is limited, so "no signal yet" is more accurate than "proven safe." Standard research-status and sterile-technique caveats apply.

Where it sits

Epitalon is one of the better-supported longevity peptides at the cell level, and now has independent replication of its core telomere mechanism, which most compounds in this space lack. What it doesn't have is human clinical outcome data. The accurate mental model: real and now-replicated preclinical signal, an unusually deep legacy research program, and no decisive human proof that the cell-level effects translate into longer or healthier human lifespan. Investigational, not approved.

The open question

For anyone tracking longevity research: now that an independent lab has reproduced the telomere effect in human cells, what's the realistic read on the human translation. Cell-culture telomere extension is a real result, but the history of aging research is full of interventions that worked in a dish and didn't carry over to people. Curious where the community lands on whether the 2025 replication moves Epitalon meaningfully forward, or whether the in-vitro-to-human gap is still the whole ballgame.

SOURCES (for fact-check):

• Epitalon = AEDG tetrapeptide from epithalamin; Khavinson, St. Petersburg Institute of Bioregulation and Gerontology, 1980s
• 2003 foundational: Khavinson, Bondarev, Butyugov, Bull Exp Biol Med (PMID 12937682) — telomerase induction + telomere elongation in telomerase-negative human fetal fibroblasts
• 2025 independent replication: Al-dulaimi, Thomas, Matta, Roberts, Brunel University London, Biogerontology 2025 (10.1007/s10522-025-10315-x) — dose-dependent telomere extension in normal + cancer human cell lines via hTERT/telomerase and ALT; figure correction Nov 2025
• All strong telomere evidence in vitro; no rigorous human clinical dose-response/outcome trial exists
• Animal lifespan + reduced tumor incidence (Anisimov/Khavinson)
• Safety: no major signal in published literature, human base limited
• Dosing = community/research convention, not evidence-established (NTN cheat sheet + Peptide Protocol Wiki)

for the first week of reta i do 2x a week .5 then the next week ill do 1g 2x a week

for the tesamorellin im doing 500 mcg which is .5mgfor the first 10 mg vial because i miscalculated the bac water and i put the wrong amount i think so im js sticking to .5mg then for the other 2 vials of 10 mg imma do 1mg before bed everynight my growth plates are still open.

The GLP class is the most active area in metabolic research, and the three compounds people actually run, semaglutide, tirzepatide, and retatrutide, represent three generations of the same idea. Each adds a receptor target, and the trial data climbs with it. This is a full breakdown of each one: how it works, what its dosing arc actually looks like, what its trials showed, and where it sits as of mid-2026.

For research and educational purposes only. Not medical advice.

The shared backbone

All three share GLP-1 receptor agonism. That's the common engine: it slows gastric emptying, suppresses appetite through central signaling, and improves glucose handling. What separates them is what each adds on top of that base.

Compound	Receptor targets	Generation
Semaglutide	GLP-1	Single agonist
Tirzepatide	GLP-1 + GIP	Dual agonist
Retatrutide	GLP-1 + GIP + glucagon	Triple agonist

Two of the three are FDA approved. Retatrutide is investigational, Phase 3, not yet approved.

Semaglutide: the single agonist

Semaglutide is the foundation of the modern class, a once-weekly GLP-1 receptor agonist marketed as Ozempic for type 2 diabetes and Wegovy for obesity. It has the longest half-life in the class at roughly 7 days, which is what allows the clean once-weekly schedule.

Mechanism. Pure GLP-1 agonism. It does one thing and does it thoroughly: appetite suppression, slowed gastric emptying, improved insulin response, suppressed glucagon. The single-pathway design is also why it's the most studied and the most predictable of the three.

The trial anchor. STEP 1 reported 14.9% mean body-weight reduction at 68 weeks on the 2.4 mg dose. Beyond weight, the SELECT trial (over 17,000 participants, roughly 4 years) established cardiovascular benefit, which is a dimension the newer compounds haven't yet matched with outcome data.

Dosing arc (research context).

Step	Dose	Role
Starter	0.25 mg	4 weeks only, GI adaptation, not therapeutic
Maintenance (T2D)	0.5 mg	Diabetes maintenance
Stop-short	1.0 mg	Retains ~73% of the 2.4 mg weight effect
Full	2.4 mg	Full Wegovy / cardiovascular / metabolic dose

The titration runs 4 weeks per step, no faster, because the entire point of the slow climb is letting GI tolerance build. The "stop-short" detail is worth knowing: 1.0 mg holds most of the weight effect of the full dose, which is why raw magnitude isn't the only thing that determines where someone lands.

Tirzepatide: the dual agonist

Tirzepatide adds GIP receptor agonism to the GLP-1 base, marketed as Mounjaro and Zepbound. Half-life around 5 days, also once-weekly.

Mechanism. The GIP component does two things: it enhances insulin secretion and modulates adipose tissue, working alongside the GLP-1 action rather than duplicating it. That dual hit is what let tirzepatide outperform semaglutide on weight in head-to-head testing, which is the one genuinely direct comparison in this whole category.

The trial anchor. SURMOUNT-1 reported 22.5% at 72 weeks on 15 mg. And critically, SURMOUNT-5 put tirzepatide directly against semaglutide in the same trial, the cleanest evidence that exists, where the dual agonist beat the single. That's the only true head-to-head among these three.

Dosing arc (research context).

Step	Dose	Role
Floor	2.5 mg	Titration floor, also a real metabolic dose
Stop-short	5 mg	Modal real-world maintenance
Value cluster	7.5 to 10 mg	~93% of max effect at 10 mg
Full	12.5 to 15 mg	Maximum

A notable detail from the dose data: 10 mg retains about 93% of the maximum effect, and the step from 10 to 15 mg adds only about 1.4 percentage points of weight loss. Most of the result is captured well before the top dose, which is why 5 mg is the most common real-world maintenance dose despite not being the maximum.

Retatrutide: the triple agonist

Retatrutide is the newest and the most powerful, adding glucagon-receptor agonism on top of tirzepatide's two targets. Still investigational, half-life around 6 days.

Mechanism. The glucagon arm is the difference-maker. On top of the GLP-1 appetite effect and the GIP insulin effect, glucagon agonism raises resting energy expenditure and drives hepatic fat oxidation. That added energy-burning component is the mechanistic reason it pushes into territory the other two don't reach, and why it posts large liver-fat reductions.

The trial anchor. TRIUMPH-1 confirmed in May 2026: 28.3% mean weight loss at 80 weeks across 2,339 patients. The standout figure is that 45.3% of participants on 12 mg lost at least 30% of body weight, which approaches outcomes historically seen only with bariatric surgery. The 104-week extension reached up to 30.3% in higher-BMI participants, and notably the weight loss had not plateaued at 80 weeks.

Dosing arc (research context).

Cohort	Ladder	Notes
Obese (trial cohort)	0.5 to 12 mg	Standard escalation ladder
Lean	0.3 to 4 mg	Body-type stratified, lower ceiling

The escalation is long: 24 to 48 weeks of active titration, held 4 weeks per step like the others. A 4 mg maintenance arm is also under study, on the logic that a lower post-titration dose may hold the result without the GI burden of the top doses.

The honest caveats. Retatrutide is not approved. NDA filing is on track for late 2026, with realistic approval late 2027 to early 2028. It carries two things the others don't: the highest GI adverse-event load at top doses, and a dysesthesia signal (altered skin sensation) that is genuinely class-distinguishing, semaglutide and tirzepatide do not report it. It's the strongest on paper and the least proven on long-term safety, both at once.

The cross-trial trap

Here's the single most important thing to understand about comparing these three: the headline numbers come from separate trials. Semaglutide's 14.9%, tirzepatide's 22.5%, and retatrutide's 28.3% were measured in different populations, over different durations (68, 72, and 80 weeks), under different trial designs. The trend tracks receptor count cleanly, single to dual to triple, but the exact gaps are directional, not precise.

Only two of these have ever been compared in the same trial: tirzepatide vs semaglutide, in SURMOUNT-5. Retatrutide has never been run head-to-head against either in a randomized trial. Its 28% sits on its own data, not on a win over the other two. The trial that would settle it, a direct retatrutide comparison, hasn't reported.

Where each sits, mid-2026

Semaglutide is the proven, cardiovascular-validated baseline with the deepest safety record. Tirzepatide is the approved efficacy leader with the only real head-to-head win in the class. Retatrutide is the investigational frontrunner on magnitude, with surgery-level numbers and the least long-term safety data, still a year-plus from possible approval. Three generations of the same mechanism, each adding a receptor and climbing the efficacy curve, with certainty running in the opposite direction of potency: the most proven is the least powerful, and the most powerful is the least proven.

The open question

For anyone tracking this: how much should the missing head-to-head weigh on the read. The receptor-count progression is clean enough that the order seems obvious, but retatrutide's 28% has never been tested directly against tirzepatide, and "investigational" is carrying real weight. Curious whether people treat the cross-trial trend as strong enough to call the ranking now, or hold off until there's a direct comparison.

For the full reconstitution, dosing, and bloodwork reference on every compound, the complete cheat sheet is here: The Only Peptide Cheat Sheet You'll Need

SOURCES (for fact-check):

• Semaglutide STEP 1: 14.9% at 68 wks (NEJM 2021); SELECT CV benefit (n=17,604, ~4 yrs)
• Tirzepatide SURMOUNT-1: 22.5% at 72 wks, 15 mg; SURMOUNT-5 head-to-head beat semaglutide
• Retatrutide TRIUMPH-1 (confirmed May 21 2026): 28.3% at 80 wks, n=2,339; 45.3% of 12mg lost ≥30%; 104-wk extension up to 30.3%, no plateau at 80 wks
• Retatrutide investigational, NDA Q4 2026, approval late 2027-early 2028; dysesthesia class-distinguishing; never tested head-to-head
• Mechanism (GLP-1 appetite / GIP insulin / glucagon energy expenditure) confirmed across Lilly trial data and reviews
• Dosing arcs and stop-short logic from NTN master cheat sheet
• All weight-loss figures from separate trials except SURMOUNT-5

theyre were rubber caps on the top that u pull off i took them off and when i was done threw them away and js stored my peps in the fridge wiull they get contaminated they still have the rubber stopper

Mitochondrial research keeps pulling attention toward two peptides that both target cellular energy but work at completely different levels: MOTS-c and SS-31. One regulates the metabolic signaling that decides how a cell uses energy. The other stabilizes the physical machinery that produces it. That difference is why they keep getting studied as a pair, and also why the "synergy" idea deserves a careful read rather than a hype one.

For research and educational purposes only. Not medical advice.

SS-31: structural protection

SS-31 (elamipretide) is a synthetic tetrapeptide, sequence D-Arg-Dmt-Lys-Phe-NH2, developed by Hazel Szeto's group at Weill Cornell. It targets cardiolipin, a phospholipid essential to the integrity of the inner mitochondrial membrane. When cardiolipin gets damaged by oxidative stress, mitochondrial efficiency drops and energy output falls with it.

By binding and stabilizing cardiolipin, SS-31 helps maintain electron transport chain efficiency, which supports ATP production while reducing reactive oxygen species. Preclinical work has linked this to improved muscle endurance, cardiac energy output, and cellular resilience under oxidative stress.

The reason SS-31 stands apart from most peptides in this space: it has real human clinical data. It has run through multiple Phase 2 and Phase 3 trials across mitochondrial disease, heart failure, and related conditions, which makes it one of the most clinically studied research peptides, not just an animal-model compound.

MOTS-c: metabolic signaling

MOTS-c is a different kind of molecule entirely. It's a mitochondrial-derived peptide, encoded within mitochondrial DNA rather than the nuclear genome, which is itself unusual. Functionally it acts as a metabolic regulator by activating AMPK, one of the body's primary cellular energy sensors.

Through that pathway, MOTS-c has been shown in experimental models to improve glucose uptake, fat oxidation, and metabolic flexibility, with one animal model reporting roughly a 30% improvement in insulin sensitivity. It also signals cells toward more energy-efficient metabolic states, broadly similar to what happens during exercise or caloric restriction, and has been associated with enhanced endurance and mitochondrial biogenesis.

The evidence caveat matters here: MOTS-c's data is largely animal-model, not human clinical. The mechanism is well characterized, the human outcomes are not yet established.

The difference in one frame

	SS-31	MOTS-c
Type	Synthetic tetrapeptide	Mitochondrial-derived peptide (from mtDNA)
Mechanism	Stabilizes cardiolipin / inner membrane	Activates AMPK metabolic signaling
Level it acts on	Structural and functional	Signaling and regulatory
Evidence base	Phase 2/3 human trials	Largely animal models
Plain-language role	Protects the machinery	Directs how energy gets used

The pairing: why it's studied, and what's actually known

This is where the source material on these two tends to overreach, so it's worth being precise. The rationale for pairing them is genuinely sound: the mechanisms don't overlap. MOTS-c works the signaling side (telling cells to ramp up metabolic demand and mitochondrial activity), while SS-31 works the structural side (keeping the mitochondria themselves efficient and protected from oxidative stress). One drives demand, the other protects the equipment meeting that demand. On paper, that's complementary rather than redundant.

What's important: that complementarity is a reasoned hypothesis, not a proven result. The available sources consistently use hedged language, the combination "may" improve mitochondrial health more than either alone, early models "suggest" the dual approach could work. There is no body of human trial data establishing that the pairing outperforms either compound by itself. The interaction is described as mechanistically non-antagonistic, meaning the two don't appear to work against each other, but "doesn't conflict" is a long way from "proven to synergize."

So the accurate framing for a research context is this: MOTS-c and SS-31 are an interesting pairing to study precisely because they hit different levels of the same system, and for anyone modeling mitochondrial function, running both lets the signaling side and the structural side be examined at once. That's a reason to study the combination, not evidence that the combination delivers more than its parts.

Where each sits

SS-31 is the more clinically validated of the two, with human trial data behind it, though still investigational and not FDA approved. MOTS-c is earlier, strong mechanistic and animal data, human outcomes unestablished. Both are research compounds, and the pairing of them is a hypothesis worth examining, not a settled protocol.

The open question

For anyone working in the mitochondrial space: does the structure-plus-signaling logic hold up as a real combination strategy, or does it mostly reflect that the two are easy to study together. The mechanisms clearly complement on paper, but the absence of human combination data leaves it open whether pairing them produces anything beyond what SS-31's clinical record already shows on its own. Curious where people land on whether the synergy is real or just tidy in theory.

SOURCES (for fact-check):

• SS-31 sequence D-Arg-Dmt-Lys-Phe-NH2, Szeto/Weill Cornell; cardiolipin mechanism; Phase 2/3 human trials (Birk et al. PNAS 2020; Thompson et al. Barth syndrome trial 2021)
• MOTS-c: mtDNA-encoded, AMPK activation, ~30% insulin sensitivity improvement in animal models; data largely preclinical
• Pairing described as mechanistically complementary, non-antagonistic, but synergy is hedged/hypothetical across all sources (PeptideWiki, Peptide-DB, Loti Labs, Tydes, PeptideDeck, 2025-2026)
• No human combination trial data exists

I have some oxytocin and I'm interested in running it alongside PT 141 but I would like to try oxytocin by itself first to see how it goes does anybody have any experience with this or dosage recommendations I have a 10 mg vial

The Complete Guide to Units, Concentration, and Not Misdosing

The single most common mistake in peptide research has nothing to do with the compound. It's the arithmetic. Someone reads "500 mcg" on a protocol, looks at a syringe marked in units, and guesses at how the two connect. That guess is where the overdoses and underdoses come from. This is the full walk-through: how to calculate concentration and units, why the same dose is a different number of units depending on the vial, how to handle the low-dose precision problem, the compounds that break the standard rules, and what actually degrades a reconstituted vial.

For research and educational purposes only. Not medical advice.

The sentence that prevents most errors

Units are not micrograms. A unit is a volume marking on the syringe, not a measure of how much compound it holds. The amount of compound in one unit depends entirely on the vial's concentration, which depends on how much bacteriostatic water was added during reconstitution. Two people running the identical compound at the identical dose can draw to completely different unit marks, purely because they reconstituted with different water volumes. Until that's internalized, every draw is a guess.

Step 1: concentration

Concentration is how much compound sits in each mL of liquid after reconstitution.

mg in vial ÷ mL of BAC water added = mg per mL

Add 2 mL of BAC water to a 10 mg vial and the concentration is 5 mg/mL. Add 3 mL to that same vial and it's 3.33 mg/mL. Same compound, same vial, different concentration, entirely because of the water. This is the root of nearly every dosing error: the unit number is meaningless until the concentration behind it is known.

Step 2: dose to units

A U-100 insulin syringe holds 1 mL across 100 units. So 100 units = 1 mL, and 1 unit = 0.01 mL. The full conversion:

target dose in mcg ÷ (mg per mL × 1000) × 100 = units to draw

Multiply mg/mL by 1000 to get mcg/mL, divide the target dose by that for the mL needed, then multiply by 100 to convert mL to units on a U-100.

A worked example, start to finish

A 10 mg vial, reconstituted with 2 mL BAC water, dosing 500 mcg:

1. Concentration: 10 ÷ 2 = 5 mg/mL (5000 mcg/mL)
2. Volume needed: 500 ÷ 5000 = 0.1 mL
3. Units: 0.1 × 100 = 10 units

So 500 mcg from this vial is 10 units. Reconstitute the same vial with 4 mL instead and 500 mcg becomes 20 units, double the marking for the exact same dose. The dose didn't change. The water did.

The same dose, different vials

This is why the unit number means nothing on its own. Each row is a real reconstitution from common protocols:

Compound	Vial	BAC	Concentration	Example dose	Units
BPC-157	10mg	2mL	5 mg/mL	500 mcg	10
Ipamorelin	10mg	2mL	5 mg/mL	300 mcg	6
TB-500	10mg	2mL	5 mg/mL	2.5 mg	50
GHK-Cu	100mg	3mL	33.3 mg/mL	2 mg	6
Cagrilintide	5mg	3mL	1.67 mg/mL	2.4 mg	144
Semax	10mg	2mL	5 mg/mL	600 mcg	12

Look at GHK-Cu: a 2 mg dose is only 6 units because the vial is concentrated at 33.3 mg/mL. Cagrilintide's 2.4 mg is 144 units, more than a full 1 mL syringe holds, because it's dilute at 1.67 mg/mL. Same formula every time, wildly different unit counts.

The shortcut worth memorizing

Once a vial is reconstituted, every dose shares the same per-unit value, so calculate it once. At a given concentration, one unit (0.01 mL) always holds:

Concentration	1 unit holds
1.67 mg/mL	~16.7 mcg
3.33 mg/mL	~33.3 mcg
5 mg/mL	50 mcg
12.5 mg/mL	125 mcg
33.3 mg/mL	~333 mcg

Find the per-unit value once, and every dose afterward is target ÷ per-unit. At 5 mg/mL, 250 mcg is 5 units, 500 mcg is 10, 750 mcg is 15. No recalculation.

Choosing a dilution: the tradeoff nobody explains

The water volume isn't just a step, it's a decision with consequences. More BAC water means a more dilute vial, which means more units per dose. That gives finer control and makes a small draw error matter less, because each unit carries less compound. Less water means a concentrated vial, fewer units per dose, smaller injection volume, but every unit carries more, so a slightly-off draw moves the dose further.

The practical rule: dilute more when precision matters (low doses, where a single unit is a big fraction of the target), concentrate more when injection volume is the concern.

There's a physical limit, though, and GHK-Cu is the perfect example. You'd often want to dilute a 100 mg vial heavily for finer control, but a standard 3 mL vial physically can't take more than about 3 mL of water with the air gap needed to draw. So 100 mg in 3 mL gives 33.3 mg/mL whether that's ideal or not. The vial size caps the dilution. Always check the physical vial before planning a fill volume, the cheat-sheet number assumes the vial can actually hold it.

The low-dose precision problem

When a dose lands at only 2 or 3 units, the math is technically right but the practical accuracy is poor. On a U-100 syringe, the gap between 2 and 3 units is a 50% dose swing, and reading to that precision on a standard barrel is hard.

Example: Ipamorelin at 100 mcg from a 5 mg/mL vial is just 2 units. A half-unit misread is a 25% dosing error.

Two fixes:

1. Use a finer syringe. A 30-unit or 50-unit insulin syringe spreads the same volume across a longer, more readable barrel, so 2 units is easier to hit precisely.
2. Dilute more. Reconstituting that Ipamorelin vial with more water pushes the same 100 mcg dose to a higher, more readable unit count, within the vial's physical limit.

If a planned dose keeps landing in low single-unit territory, that's the signal to change the dilution or the syringe, not to squint harder.

The exceptions that break the standard flow

Most peptides follow the BAC-water flow above. A few don't:

• IGF-1 LR3 and DES reconstitute with 0.6% acetic acid, not bacteriostatic water. This is the exception people most often miss, and using BAC water can compromise the peptide.
• SS-31, MOTS-c, and Ara-290 use isotonic (NaCl-containing) bacteriostatic water, which also reduces sting on injection.
• Blends (CJC/Ipamorelin, GLOW, KLOW, Cagri/Sema) hold two compounds in one vial at a fixed ratio. The unit math still works off total volume, but the dose is anchored to whichever compound the protocol specifies, and the second rides along at the blend's set ratio. That fixed ratio is the tradeoff of a blend, covered in its own discussion.

Technique that protects the math

Accurate units mean nothing if the solution itself is compromised:

• Swirl, never shake. Gently swirl or roll until the powder dissolves and the solution runs clear. Shaking foams the liquid and can shear delicate peptides. Foam also makes accurate drawing impossible until it settles.
• Room temperature first. Let a cold vial reach room temperature before adding water, condensation inside a cold vial introduces moisture that accelerates breakdown. For a frozen lyophilized vial, let it reach fridge temperature first, never add water to frozen powder.
• Clean every pierce. Swab the stopper with alcohol and let it dry before each draw, use a fresh needle each time. Contamination is the leading cause of degradation in practice, and the preservative in BAC water only slows microbial growth, it doesn't replace clean technique.

Storage and degradation: why the rules exist

The handling rules aren't arbitrary. Here's what's actually happening:

The 28-day refrigerated window. Reconstituted vials generally hold about 28 days at 2 to 8°C. That number isn't random, it tracks the pharmaceutical beyond-use date (USP 797) for preserved multi-dose preparations. Bacteriostatic water contains 0.9% benzyl alcohol, which inhibits microbial growth for roughly 28 days, after which the antimicrobial effect declines and the vial should be discarded. Plain sterile water has no preservative and is single-use only.

Never freeze a reconstituted vial. Freezing forms ice crystals that physically disrupt the peptide's folded structure. Each freeze-thaw cycle can cut activity meaningfully. Lyophilized (dry) vials belong in the freezer for long-term storage, reconstituted (liquid) vials never do, they stay in the fridge.

Light and heat are the main enemies. UV and visible light break bonds in aromatic amino acids (tryptophan is most sensitive). Heat accelerates hydrolysis and oxidation. Keep reconstituted vials refrigerated and protected from light, amber vials or foil wrapping if the vial is clear. Never leave a reconstituted vial sitting on a bench under light.

When to discard regardless of date. Cloudiness, visible particulates, or unexpected color change all mean discard, no matter how many days are left. One carve-out: GHK-Cu legitimately shows a faint blue-green tint from the copper complex, that color is normal for it and only it. For everything else, a properly reconstituted solution should be clear and colorless.

Logging

A draw log is the difference between a readable protocol and guesswork three weeks later. The fields that actually get used:

Date reconstituted | Compound | Vial mg | BAC mL | Concentration | 
Dose | Units | Injection site | Notes

Logging the concentration and reconstitution date next to the dose is the part people skip. A unit count without its concentration is unreadable later, and without the reconstitution date there's no way to track the 28-day window.

Pulling it together

The compound matters less than the arithmetic for dosing accuracy. The whole system is two steps: find mg/mL from the water added, then convert the target dose to units through that concentration. Get those right and the unit count is correct every time. The dilution choice, the syringe size, and the storage rules are all just protecting that core calculation, the dilution so the units are readable, the technique and storage so the compound in the vial is still what the math assumes. Run the numbers, log them, and the most common mistake in the field stops being a risk.

Hello, everyone new into here but not in the World of performance enhancements.

I am a pro athlete that is/wants to get back into top tier performance peak. I want to know for peptides which ones you would consider for building muscle & endurance (if there are any for endurance). I used to take Turinabol ,HGH & Test Suspension but I would like to stay away from those and focus on peptides. Let me know your thoughts, etc. appreciate it.

SWIM tried oral KPV in the past at very low doses of 50mcg and by day 5 SWIM’s gut felt amazing, libido was up, pooping wonderfully multiple times a day, skin looked amazing.. but… it gave SWIM pretty bad anhedonia. Unfortunately, this made SWIM stop it.

Anyone ever experience that? If so, how to manage or keep doing it safely ?

I have been taking nad+ 100 mg three times a week and just recently got some mots-c I hear that these two work great together what is the dosage for mots-c can anybody share their experience

I've been digging through older discussions and it seems like a lot of people eventually end up comparing Ipamorelin and CJC-1295.

Some people describe Ipamorelin as the cleaner, simpler option, while others seem to think the real benefits come from combining it with CJC-1295 rather than using either one on its own.

For those who've actually spent some time using one or both, what ultimately influenced your choice?

Was it better recovery, improved body composition, sleep quality, growth hormone support, fewer side effects, or something else?

I'd be interested to hear from people with enough firsthand experience to compare them and explain what made them stick with one approach over the other.